Screening of antibacterial small molecule and phage combinations

National Center For Advancing Translational Sciences

Investigators

Abstract

Monotherapy for bacterial infectious is failing at an increasing rate, and often relies on second or third line therapies. To address this, the project team has begun screening combinations of approved antibacterials or antibacterial+phage combinations to suggest novel combinations for evaluation in the treatment of bacterial infections. Additionally, the emergence and spread of multidrug-resistant bacterial infections continues to hamper current treatment of bacterial infections, and may risk the emergence of infections refractive to therapy. The project team has worked to leverage its high-throughput matrix platform to assess drug-drug combinations and drug-phage combinations for further pre-clinical development.